Jump to content

Domagrozumab

From Wikipedia, the free encyclopedia
Domagrozumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetGDF-8
Clinical data
Other namesPF-06252616
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6366H9826N1690O2008S46
Molar mass143639.22 g·mol−1

Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]

This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.[3]

References

[edit]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  3. ^ https://www.pfizer.com/news/press-release/press-release-detail/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duchenne_muscular_dystrophy [bare URL]